BIOMAT Database Logo BIOMAT Database Logo

Introduction: examination of clinical and preclinical pharmacologic data relating to abuse liability of l-deprenyl (selegiline). 1994

S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250
D019966 Substance-Related Disorders Disorders related to substance use or abuse. Chemical Dependence,Drug Abuse,Drug Addiction,Drug Dependence,Drug Habituation,Drug Use Disorder,Drug Use Disorders,Organic Mental Disorders, Substance-Induced,Substance Abuse,Substance Dependence,Substance Related Disorder,Substance Use,Substance Use Disorder,Substance Use Disorders,Prescription Drug Abuse,Substance Addiction,Abuse, Drug,Abuse, Prescription Drug,Abuse, Substance,Addiction, Drug,Addiction, Substance,Chemical Dependences,Dependence, Chemical,Dependence, Drug,Dependence, Substance,Dependences, Chemical,Disorder, Drug Use,Disorder, Substance Related,Disorder, Substance Use,Disorders, Substance Related,Drug Abuse, Prescription,Habituation, Drug,Organic Mental Disorders, Substance Induced,Related Disorder, Substance,Related Disorders, Substance,Substance Abuses,Substance Uses,Use, Substance

Related Publications

S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Therapy with l-deprenyl (selegiline) and relation to abuse liability.
December 1994, Clinical pharmacology and therapeutics,
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Evaluation of physical dependence liability of l-deprenyl (selegiline) in animals.
December 1994, Clinical pharmacology and therapeutics,
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Biochemical actions of l-deprenyl (selegiline).
December 1994, Clinical pharmacology and therapeutics,
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats.
November 1990, Neuropharmacology,
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.
December 1994, Clinical pharmacology and therapeutics,
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
October 1985, Acta neurologica,
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Low dose selegiline (L-Deprenyl) in social phobia.
January 1998, Depression and anxiety,
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Anti-apoptotic function of L-(-)deprenyl (Selegiline) and related compounds.
January 2000, Neurobiology (Budapest, Hungary),
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
Metabolism of selegiline [(-)-deprenyl)].
January 2014, Current medicinal chemistry,
S R Goldberg, and S Yasar, and J Bergman, and M B Youdim
What is it that l-deprenyl (selegiline) might do?
December 1994, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!